Background Bladder cancer (BCa) is one of the most prevalent malignancies globally.
Previous study has reported the inhibitory effect of methyltransferase-like 14 (METTL14) on …

(1) Background: Intravesical mitomycin-C (MMC) combined with hyperthermia is
increasingly used in non-muscle invasive bladder cancer (NMIBC), especially in the context …

Nanoformulations are regarded as a promising tool to enable the efficient delivery of active
pharmaceutical ingredients to the target site. One of the best-known and most studied …

Introduction This large-scale, US-based study characterized real-world treatment patterns
and clinical outcomes in patients with advanced or metastatic urothelial carcinoma (aUC) …

Bladder cancer (BCa) and prostate cancer (PCa) are some of the most common cancers in
the world. In both BCa and PCa, the diagnosis is often confirmed with an invasive technique …

Bladder cancer (BCa) is a common malignancy in the urinary system. Ras‐related protein
Rab‐27A (RAB27A) and Ras‐related protein Rab‐27B (RAB27B) have been verified to be …

Background Bladder cancer is very common worldwide. PIGT is a subunit of the
glycosylphosphatidylinositol transamidase which involves in tumorigenesis and …

Bladder cancer is the tenth most common cancer worldwide, where its burden remains a
challenge and needs new novel therapies. Several reports indicate expression of CYP4Z1 …

Simple Summary The aim of this study was to present and analyze the up-to-date literature
describing the epidemiology, genetics, and histopathology of bladder cancer, as well as the …

Bladder cancer (BCa) is one of the most common malignancies worldwide. Although
multiple efforts have been made, the 5‐year survival rate of patients with BCa remains …